Skip to main content
The Markets by Proactive
Go to Proactive UK
Proactive UK has moved. Proactive’s coverage of London’s small caps continues on proactiveinvestors.com Go there →
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Coverage of London’s small caps continues on proactiveinvestors.com
Go to Proactive UK
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK
Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK

Archive

Proactive news snapshot: Alliance Pharma, Avacta, Obtala, Caledonia Mining...

A glance at some of the day's highlights from the Proactive Investors newswire

Alliance Pharma plc (LON:APH) has launched the UK’s only prescription treatment for vomiting and nausea during pregnancy.

Avacta Group Plc (LON:AVCT) says it has made “significant progress” in its partnering discussions and expects to deliver at least one “substantial” licensing deal before its Affimer technology reaches the clinic.

The order book for Obtala Ltd’s (LON:OBT) trading business remains very healthy at more than US$10mln, the company said in a third quarter update.

Caledonia Mining Corporation PLC (LON:CMCL) has declared a quarterly dividend of US$0.06875 per share. The shares will go ex-dividend on 11 October, and the record date is 12 October.

Tekcapital PLC (LON:TEK) has raised US$1.1mln through a share placing to fund the commercialisation of its portfolio, while also announcing the appointment of a chairman to the board of one of its companies.

Julia Ralston has officially taken up her position as an executive director of Cello Health plc (LON:CLL), the communications and consulting group. Formerly chief executive of the business’ US arm, she joined the company in 2011 following the acquisition of MedErgy. “Julia's presence on the board will ensure appropriate levels of governance and control around Cello's expanding US business,” the company said.

Blockchain and crypto currency investor KR1 Plc (AQSE:KR1) has sold out of two of its investments at healthy prices. The last of KR1’s holding in Golem (GNT) was sold for 22c per token, raising US$134,000.

Bacanora Lithium PLC (LON:BCN) has revealed the findings of an external report commissioned to provide an analysis of the significant beneficial holders of the company's shares as at 11 September 2018. The largest holder is M&G, with 10% of the shares, followed by Blackrock, with 9.8%. Then comes Hanwa with 9.2%, Cadence Minerals and Igneous with 7.4% each.

AfriTin Mining Limited (LON:ATM) is to buy two more tin and tantalum licences to expand its footprint in Namibia.

App management platform appScatter Group PLC has appointed Andrew Bushby as a non-executive director. He brings 25 years of experience in the industry working previously for Oracle Corporation, Sun Microsystems and Novell.

Block Energy Plc (LON:BLOE) has appointed Christopher Brown as a non-executive director to replace Tim Parson. Brown is a consultant with nearly 40 years' experience across the international upstream oil and gas sector.

ECR Minerals PLC (LON:ECR) said the option period for due diligence work on the Iceberg gold project in Western Australia has been extended to allow for a thorough review of historical data supplied by the vendors.

Circle Property PLC (LON:CRC) said it has renegotiated a lease with a major tenant at its biggest asset, Kents Hill Business Park in Milton Keynes.

Ergomed PLC (LON:ERGO) told investors Andrew Mackie is stepping down as chief business officer following the company's announcement in April to shift its strategy to focus on services. It also announced that Michael Spiteri, who was responsible for digital strategy at Santander's UK corporate and commercial banking business, would become non-executive director.

Shareholders of Abzena PLC (LON:ABZA) have voted through all the necessary proposals to enable the takeover of the company by WCAS to go through.

Redx Pharma Plc’s (LON:REDX) new management team plans to focus its cash resources on progressing its drug leads in oncology and fibrotic disease to clinical proof-of-concept in 2019.

Advertisement
The Markets
by Proactive
Proactive UK has moved.
Small-cap coverage continues on .com
Go to Proactive UK